论文部分内容阅读
目的为提高直肠癌术后化疗效果,以帮助患者延长生命,提高生存质量。方法 2011年1月-2014年12月医院收治直肠癌患者34例,给予患者术后基础放疗和化疗。化疗取FOLFOX4方案。统计全部患者的临床疗效及基本临床数据,记录治疗期间患者的不良反应情况,对比患者治疗前后自然杀伤细胞活动性和CD8+淋巴细胞变化情况,以KPS评分判定患者化疗前后生存质量变化。结果以FOLFOX4方案化疗直肠癌术后患者,肿瘤进展平均用时28.3个月,化疗前后自然杀伤细胞活动性和CD8+淋巴细胞变化率差异无统计学意义(P>0.05);不良反应多为恶心呕吐、感觉神经异常、WBC水平下降,反应程度多为Ⅰ~Ⅱ级;患者化疗后KPS评分提高24例(70.59%)。结论直肠癌术后,给予患者基础放疗和FOLFOX4化疗,药物可耐受,化疗效果良好,有利于保护患者机体抵抗力,提高患者生存率及生活质量,值得临床推广。
The purpose is to improve postoperative chemotherapy in rectal cancer to help patients prolong their life and improve their quality of life. Methods From January 2011 to December 2014, 34 patients with rectal cancer were admitted to the hospital for postoperative radiotherapy and chemotherapy. Chemotherapy to take FOLFOX4 program. The clinical efficacy and basic clinical data of all patients were recorded. The adverse reactions of patients during treatment were recorded. The natural killer cell activity and CD8 + lymphocyte changes before and after treatment were compared. The KPS scores were used to determine the changes of patients’ quality of life before and after chemotherapy. Results The patients with postoperative FOLFOX4 regimen had an average tumor progression of 28.3 months. There was no significant difference in the activity of natural killer cells and the rate of change of CD8 + lymphocytes before and after chemotherapy (P> 0.05). The adverse reactions were mostly nausea and vomiting, Sensory nerve abnormalities, WBC levels decreased, the degree of response were mostly grade Ⅰ ~ Ⅱ; KPS score improved in patients after chemotherapy in 24 cases (70.59%). Conclusions Postoperative rectal cancer is given to patients with basic radiotherapy and FOLFOX4 chemotherapy. The drug can be tolerated and the chemotherapy effect is good. It is good for protecting the patient’s body immunity, improving the patient’s survival rate and quality of life, and is worthy of clinical promotion.